Two manufacturers launched their docetaxel products at CPhI last
week, each trying to stake their claim in the market in
anticipation of patent expiries on Sanofi-Aventis' Taxotere
(docetaxel) towards the end of the year.
Bioxel Pharma is the latest company to submit a Drug Master File
(DMF) to the US Food and Drug Administration (FDA) for docetaxel in
the lead up to the patent expiring on Sanofi-Aventis' version of
the cytotoxic chemical at the...
Canadian pharma manufacturer Bioxel has announced it has received
several orders for its paclitaxel product - a taxane-based drug
effective to treat cancer - from two European customers
representing a total of CAD$630,000 (€420,000).
Canadian pharma manufacturer Bioxel has announced the filing of a
second international patent application to secure the synthesis of
paclitaxel and decetaxel - two taxane-based drugs effective against
cancer.
Bioxel, a company which manufactures and markets taxane active
pharmaceutical ingredients (APIs) used in chemotherapeutic drugs,
has turned to two contract manufacturing companies to scale up
production.
French drug delivery company Novagali Pharma has completed
early-stage clinical testing of an oral formulation of paclitaxel,
a widely used cancer drug usually delivered by intravenous
infusion.
Novagali Pharma, a biopharmaceutical company developing innovative
drug delivery systems, has started a Phase I clinical trial in
patients with advanced cancer for its oral formulation of the
cancer drug paclitaxel.
A new method to produce paclitaxel, the potent anti-tumour drug
from yew needles has been discovered which provides a solution to
the problem of finding a viable source of the raw material at a
relatively low cost.
The taxane class of cancer drugs has established itself as a
mainstay in the treatment of a range of solid tumours, but to date
there are still only two of these compounds on the market.
DFB Pharmaceuticals has appointed Magnus Precht as the new
president at Phyton, a company specialising in plant cell
fermentation for the production of pharmaceutical which it acquired
last year.